ABL Bio receives upfront payment and equity investment from Eli Lilly
Harbour BioMed and Yantai Lannacheng Biotechnology form collaboration to advance next-gen RDCs
Repare Therapeutics sells RP-3467 asset to Gilead Sciences for up to USD30m
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer
BioNTech completes acquisition of CureVac
BiBBInstruments reports additional US orders during targeted EndoDrill GI launch
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL
Genmab completes tender offer for Merus and opens subsequent offering period
NanOlogy launches drug development program for diffuse intrinsic pontine glioma treatment
Privo Technologies doses first patient in first-in-human clinical trial of PRV131